A Phase III Study of CS-8958 - A randomized double-blind comparative study of CS-8958 in patients with influenza virus infection aged 10 to 19 years -

Trial Profile

A Phase III Study of CS-8958 - A randomized double-blind comparative study of CS-8958 in patients with influenza virus infection aged 10 to 19 years -

Completed
Phase of Trial: Phase III

Latest Information Update: 04 Jun 2016

At a glance

  • Drugs Laninamivir (Primary)
  • Indications Influenza virus infections
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Daiichi Sankyo Company
  • Most Recent Events

    • 04 Jun 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top